Business
Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress
NS Pharma, Inc. (NS Pharma), a biopharmaceutical leader in rare disease and subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that the National Center of Neurology and Psychiatry (NCNP, Kodaira City; President, Kazuyuki Nakagome) presented 3.5-year efficacy and safety data from the open-label extension of an investigator-initiated clinical trial of brogidirsen (NS-089/NCNP-02) for the treatment of Duchenne muscular dystrophy (DMD) at the 30th annual International Congres
About this update from Nippon Shinyaku Co., Ltd.
[{"type":"text","content":"PARAMUS, N.J., Oct. 14, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a biopharmaceutical leader in rare disease and subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that the National Center of Neurology and Psychiatry (NCNP, Kodaira City; President, Kazuyuki Nakagome) presented 3.5-year efficacy and safety data from the open-label extension of an investigator-initiated clinical trial of brogidirsen (NS-089/NCNP-02) for the treatment of Duchenne muscular dystrophy (DMD) at the 30th annual International Congress of the World Muscle Society from October 7 to 11, 2025.","length":612,"tagName":"p"},{"type":"image","alt":"Logo for NS Pharma, Inc. (PRNewsfoto/NS Pharma, Inc.)","displaySize":"","headline":null,"caption":"Logo for NS Pharma, Inc. (PRNewsfoto/NS Pharma, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":67,"url":"https://media.zenfs.com/en/prnewswire.com/354d640585c26a59af279124b4668afd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Y8ytKgxFPFBHoMHMWa_Pbg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/354d640585c26a59af279124b4668afd","width":400,"height":67}},"href":"https://mma.prnewswire.com/media/2377806/NS_Pharma_Inc__Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Brogidirsen is an antisense oligonucleotide co-discovered by Nippon Shinyaku and NCNP as an investigational therapy for DMD patients with dystrophin gene mutations that are amenable to exon 44 skipping.","length":202,"tagName":"p"},{"type":"text","content":""These long-term motor function data suggest the potential for brogidirsen to slow disease progression in DMD patients amenable to exon 44 skipping and support the robust increases in dystrophin production seen earlier in the trial," said NS Pharma President, Yukiteru Sugiyama, Ph.D. "We are proud to offer hope to families and continue to demonstrate our commitment to the DMD community","length":403,"tagName":"p"},{"type":"text","content":"The presented data are based on the investigator-initiated clinical trial conducted by NCNP and its extension study conducted by Nippon Shinyaku. These studies evaluated the efficacy and safety of brogidirsen in 6 participants who received weekly IV dosing of brogidirsen.","length":272,"tagName"...